We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This change lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow experienced a drop of 0.2%, and the technology-dominated Nasdaq saw a decrease of 0.24%.
Shares of the drugmaker have appreciated by 8.03% over the course of the past month, outperforming the Medical sector's loss of 0.56%, and the S&P 500's gain of 0.94%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is expected to report EPS of $5.05, up 26.88% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $3.16 billion, indicating a 8.65% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.4 per share and a revenue of $11.98 billion, signifying shifts of +4280.95% and +8.69%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.41% upward. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 24.99. This signifies a premium in comparison to the average Forward P/E of 18.93 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 106, placing it within the top 43% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
Vertex Pharmaceuticals (VRTX - Free Report) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This change lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow experienced a drop of 0.2%, and the technology-dominated Nasdaq saw a decrease of 0.24%.
Shares of the drugmaker have appreciated by 8.03% over the course of the past month, outperforming the Medical sector's loss of 0.56%, and the S&P 500's gain of 0.94%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is expected to report EPS of $5.05, up 26.88% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $3.16 billion, indicating a 8.65% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.4 per share and a revenue of $11.98 billion, signifying shifts of +4280.95% and +8.69%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.41% upward. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 24.99. This signifies a premium in comparison to the average Forward P/E of 18.93 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 106, placing it within the top 43% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.